UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 76

of 'Induction therapy for acute myeloid leukemia in younger adults'

76
TI
Incidence of Philadelphia-chromosome in acute myelogenous leukemia and biphenotypic acute leukemia patients: And its role in their outcome.
AU
Atfy M, Al Azizi NM, Elnaggar AM
SO
Leuk Res. 2011;35(10):1339.
 
BACKGROUND: Philadelphia-chromosome positive acute myeloid leukemia (Ph+ AML) is a rare entity and patient prognosis is poor, with short median survival. Biphenotypic acute leukemia (BAL) is a rare disorder that is difficult to diagnose and it displays features of both myeloid and lymphoid lineage. The aim of this study was to highlight the incidence of Philadelphia chromosome and its presence in cases of acute myeloid and biphenotypic leukemia and determine its role in the outcome of these leukemias.
SUBJECTS AND METHODS: This study examined 464 subjects with newly diagnosed acute myeloid leukemia: 312 were males and 152 were females. All individuals were subjected to immunophenotyping and conventional karyotyping. FISH was used in failed cases of conventional cytogenetics analysis to quantify disease and to prove positive BCR-ABL fusion gene.
RESULTS: the incidence of Ph+ chromosome was found to be higher in BAL (38.4%) than in AML (1.99%). There was statistically significant difference according to the age and the mediansurvival time between the two groups.
CONCLUSION: Detection of specific chimeric transcripts in AML and BAL at the time of diagnosis was crucial since it plays an important role for accurate risk stratification and treatment management.
AD
Flow Cytometry and Cytogenetic Units, Department of Clinical Pathology, Zagazig University, 20 Atfy Street, Kawmeya, Zagazig, Sharkia Governate 44155, Egypt. mahaatfi@hotmail.com
PMID